Survival in Patients With Severe Ischemic Cardiomyopathy Undergoing Revascularization Versus Medical Therapy: Association With End-Systolic Volume and Viability

D. H. Kwon, R. Hachamovitch, Z. B. Popovic, R. C. Starling, M. Y. Desai, S. D. Flamm, B. W. Lytle, T. H. Marwick
2012 Circulation  
Background-The value of assessment of viability as a predictor of surgical revascularization benefit in ischemic cardiomyopathy has recently been questioned in a large trial. We sought to determine whether the contribution of viability as myocardial scar burden (SB) to predict revascularization outcomes could be modulated by end-systolic volume index (ESVi). Methods and Results-Delayed hyperenhancement-MRI was obtained in 450 patients with Ն70% stenosis in Ն1 epicardial coronary artery (75%
more » ... median age, 62.8Ϯ10.7 years; mean left ventricular ejection fraction, 23Ϯ9%; mean ESVi, 115Ϯ50 mL) from 2002 to 2006. SB was quantified as scar percentage (infarcted mass/total left ventricular mass). Subsequent surgical revascularization was performed in 245 (54%) patients and subsequent percutaneous coronary interventions were performed in 28 (6%) patients. A propensity score was developed for revascularization. Cox proportional hazards models of all-cause mortality were used for risk adjustment. Over a mean follow-up of 5.8Ϯ2.7 years, 186 (41%) deaths occurred. After adjusting for prior revascularization, sex, diabetes, age, use of cardiac resynchronization therapy, implantable cardioverter defibrillator, mitral regurgitation, and mitral valve procedures; an interaction between scar percentage and ESVi (Pϭ0.016) and an interaction between post-MRI revascularization and ESVi (Pϭ0.0017) were independently associated with mortality. ESVi demonstrated a significant interaction with revascularization and female sex, such that enhanced survival was associated with ESVi. ESVi also showed an interaction with SB; better survival was associated with lower volumes and less scar. Conclusions-ESVi and SB provide independent, incremental prognostic value in patients with severe ischemic cardiomyopathy. The risk associated with SB should not be assessed in isolation. (Circulation. 2012;126[suppl 1]:S3-S8.)
doi:10.1161/circulationaha.111.084434 pmid:22965991 fatcat:wstxeyusezdflpsqopup64zfr4